Protéus and the leading fine chemical company PCAS have teamed up to create PCAS Biosolution to integrate chemistry and biotechnology and provide a unique and exclusive offering to the pharmaceutical industry. The mission of PCAS Biosolution is to provide significant value to drug developers by designing, developing and implementing new cost-effective and scaleable manufacturing routes to APIs and intermediates which combine both chemistry and biocatalysis.
PCAS Biosolution combines and integrates multidisciplinary expertise, proprietary technologies and multi-scale production capabilities in both chemistry and biotechnology. It focuses on the synthesis of APIs, intermediates and building blocks using chemo-biocatalytic manufacturing routes. Biocatalytic steps provide scalability, versatility and a high chemo-, regio-, stereo- and enantioselectivity.
Benefits include the ability to produce complex intermediates and APIs using scaleable routes, reduce manufacturing costs, improve productivity, reduce byproducts and develop competitive green chemistry processes. Biocatalysts and processes developed are generally proprietary, thus providing opportunities to our customers to reinforce and extend the lifetime of their existing intellectual property.
Click on the logo below to access to our web site dedicated to PCAS Biosolution.